Launched in March 2020 to develop innovative therapeutics with a focus on oncology, AmMax is a clinical-stage company successfully leveraging its expertise in translational and clinical development to build a strong oncology portfolio focused on sizeable market opportunities via licensing and partnerships. The Company’s portfolio, anchored by a novel next generation antibody-drug conjugate (ADC), has the potential to create new standards of care by targeting a tumor-associated antigen overexpressed across a broad range of solid tumors. The AmMax team has established a solid track record of advancing its program development, including the completion of multiple clinical studies that produced positive proof-of-concept data for its second program for the treatment of tenosynovial giant cell tumor (TGCT). Developed as a “local administration for a local disease” the program has the potential to bring significant clinical benefits to a much broader set of TGCT patients.